Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Previously Treated Myelodysplastic Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01235572
What this trial is testing

Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy

Who this might be right for
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)+14 more
Fred Hutchinson Cancer Center 200
Testing effectiveness (Phase 2)Study completedNCT00423514
What this trial is testing

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center 38
Testing effectiveness (Phase 2)Study completedNCT00357084
What this trial is testing

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Who this might be right for
Cancer
Fred Hutchinson Cancer Center 53
Testing effectiveness (Phase 2)WithdrawnNCT01652014
What this trial is testing

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+51 more
University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Ended earlyNCT00589316
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+7 more
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)UnknownNCT00043134
What this trial is testing

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT03953898
What this trial is testing

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+4 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Study completedNCT01869114
What this trial is testing

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+7 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 57
Not applicableStudy completedNCT00248547
What this trial is testing

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Who this might be right for
Cancer
OHSU Knight Cancer Institute 40
Testing effectiveness (Phase 2)Study completedNCT00317785
What this trial is testing

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndromes
Fred Hutchinson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT00005804
What this trial is testing

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
Fred Hutchinson Cancer Center
Early research (Phase 1)Study completedNCT00004263
What this trial is testing

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic Syndromes
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT00526292
What this trial is testing

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center 12
Testing effectiveness (Phase 2)Looking for participantsNCT02727803
What this trial is testing

Personalized NK Cell Therapy in CBT

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia+23 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT00003572
What this trial is testing

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Large-scale testing (Phase 3)Study completedNCT00003938
What this trial is testing

Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients

Who this might be right for
Cancer
European Organisation for Research and Treatment of Cancer - EORTC 115
Early research (Phase 1)Study completedNCT00357708
What this trial is testing

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+10 more
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00017550
What this trial is testing

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Genzyme, a Sanofi Company
Early research (Phase 1)Study completedNCT00217646
What this trial is testing

Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

Who this might be right for
Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia+21 more
National Cancer Institute (NCI) 36
Next Page
26